Researchers have generated functional hepatocytes from human stem cells, transplanted them into mice with acute liver injury, and shown the ability of these stem-cell-derived human liver cells to function normally and increase survival of the treated animals. This promising advance in the development of cell-based therapies to treat liver failure resulting from injury or disease relied on the development of scalable, reproducible methods to produce stem-cell-derived hepatocytes in bioreactors, as described in an article pubished online on July 9, 2013 in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. First author Dr. Massoud Vosough and coauthors, including senior author Dr. Hossein Baharvand, demonstrate a large-scale, integrated manufacturing strategy for generating functional hepatocytes in a single suspension culture grown in a scalable stirred bioreactor. In the article, the authors describe the method used for scale-up, differentiation of the pluripotent stem cells into liver cells, and characterization and purification of the hepatocytes based on their physiological properties and the expression of liver cell biomarkers. Dr. David C. Hay, MRC Centre for Regenerative Medicine, University of Edinburgh, U.K., comments on the importance of Vosough et al.'s contribution to the scientific literature in his editorial in Stem Cells and Development entitled "Rapid and Scalable Human Stem Cell Differentiation: Now in 3D." The researchers "developed a system for mass manufacture of stem-cell-derived hepatocytes in numbers that would be useful for clinical application," creating possibilities for future "immune-matched cell-based therapies," says Dr. Hay. Such approaches could be used to correct mutated genes in stem cell populations prior to differentiation and transplantation, he adds.
Login Or Register To Read Full Story